 I'm Bill Brough in San Francisco, California, reporting from the 10th annual ASCO-GU meeting. A common drug appears to improve survival in hypertensive patients with metastatic renal cell carcinoma. That's the news from the 10th meeting of GU-ASCO. According to a retrospective study, the use of angiotensin system inhibitors, or Improved the survival of patients with metastatic renal cell carcinoma by nine months compared with patients who were not receiving these types of agents. Survival was even higher in patients receiving ASIs, along with treatment targeting their Bejaf pathway. Hypertension is a common condition in the United States, and this is the largest analysis to date evaluating the role of ASIs on outcomes in patients with cancer. For more news, visit our Facebook page at www.kidneycancer.org, reporting from San Francisco. With Keri Konoski, I'm Bill Brough.